First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: May 14, 2024

Gemini Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gemini Therapeutics Inc
Research & Development Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
G
Gemini Therapeutics Inc
NASDAQ:GMTX
Research & Development
-$33.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7B
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$6.1B
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.7B
CAGR 3-Years
-26%
CAGR 5-Years
-21%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.6B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is Gemini Therapeutics Inc's Research & Development?
Research & Development
-33.4m USD

Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Research & Development amounts to -33.4m USD.

What is Gemini Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 1Y
31%

Over the last year, the Research & Development growth was 31%.